Oragenics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 14.29 million compared to USD 15.71 million a year ago. Basic loss per share from continuing operations was USD 7.11 compared to USD 8.09 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | +0.12% | +18.84% | -70.85% |
05-16 | Sector Update: Health Care Stocks Ease Thursday Afternoon | MT |
05-16 | Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise | MT |
1st Jan change | Capi. | |
---|---|---|
-70.85% | 7.35M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.32% | 22.28B | |
-5.48% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- OGEN Stock
- News Oragenics, Inc.
- Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022